Share Price and Basic Stock Data
Last Updated: November 3, 2025, 11:35 pm
| PEG Ratio | -7.54 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Dhanvantri Jeevan Rekha Ltd operates within the Hospitals & Medical Services industry, reporting a current price of ₹26.4 and a market capitalization of ₹10.8 Cr. The company has shown a fluctuating revenue trend over the past quarters, with sales rising from ₹4.10 Cr in June 2022 to ₹5.15 Cr in December 2023. The most recent quarter, March 2024, recorded sales of ₹5.44 Cr. Annual revenues have also shown growth, with a total sales figure of ₹17.68 Cr for the fiscal year ending March 2023, projected to reach ₹20.46 Cr by March 2024, and ₹22.65 Cr by March 2025. This upward trajectory indicates a robust demand for its services, although the operating profit margin (OPM) remains relatively low at 2.54%. Such performance reflects the competitive nature of the healthcare sector, where operational efficiency is critical to maximize profitability amidst rising costs.
Profitability and Efficiency Metrics
The profitability metrics of Dhanvantri Jeevan Rekha Ltd reveal a challenging landscape. The company reported a net profit of ₹0.41 Cr for the fiscal year ending March 2023, with a return on equity (ROE) of 5.20% and a return on capital employed (ROCE) of 5.82%. Despite these positive figures, the operating profit has been inconsistent, with a recorded low of -1.76% in September 2022 and a high of 9.13% in December 2023. The interest coverage ratio stood at an impressive 113.00x, indicating that the company is well-positioned to meet its interest obligations, as there are no borrowings reported. However, the cash conversion cycle (CCC) of 29.01 days suggests room for improvement in managing working capital. Overall, these metrics indicate that while the company is generating profit, the efficiency in converting sales into operating profit remains a concern.
Balance Sheet Strength and Financial Ratios
Dhanvantri Jeevan Rekha Ltd displays a strong balance sheet with no reported borrowings, standing at ₹0.00 Cr, which signifies a debt-free status. The company’s total assets amounted to ₹14.78 Cr as of March 2025, with reserves growing to ₹5.98 Cr. The asset turnover ratio improved to 1.52, reflecting better utilization of assets to generate revenue. The price-to-book value ratio of 0.84x indicates that the stock is trading below its book value, suggesting potential undervaluation. The current ratio of 1.46 and quick ratio of 1.41 further underscore liquidity adequacy, allowing the company to cover short-term obligations effectively. However, the operating profit margin (OPM) of 2.54% and net profit margin of 2.25% remain lower than the industry average, highlighting the need for improved operational efficiency to enhance profitability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Dhanvantri Jeevan Rekha Ltd reveals a stable structure, with promoters holding 19.65% and the public holding 80.37% as of June 2025. This distribution indicates a strong public interest in the company, as the number of shareholders reached 1,677, showing a slight increase from previous periods. The absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) may imply a lack of institutional confidence, which could affect liquidity and market perception. Nonetheless, the consistent promoter holding suggests a commitment to the company’s growth. The absence of dividend payouts over recent fiscal years reflects a focus on reinvesting profits into the business, which may be a strategic move to strengthen operations and expand service offerings in a highly competitive market.
Outlook, Risks, and Final Insight
The outlook for Dhanvantri Jeevan Rekha Ltd appears cautiously optimistic, with projected revenue growth and a stable financial foundation. However, risks include the low operating profit margins and the need to enhance operational efficiency to compete effectively in the healthcare sector. Additionally, the absence of institutional backing may limit the company’s ability to attract significant investments for expansion. If the company successfully improves its profit margins and operational efficiency, it could enhance shareholder value and market perception. Conversely, persistent inefficiencies or market volatility could hinder growth prospects. Overall, Dhanvantri Jeevan Rekha Ltd must navigate these challenges effectively to capitalize on its current growth trajectory and bolster investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Dhanvantri Jeevan Rekha Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 45.7 Cr. | 136 | 195/135 | 6.14 | 115 | 2.57 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 24.9 Cr. | 23.7 | 37.6/0.00 | 25.5 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 12.6 Cr. | 12.2 | 23.4/12.0 | 140 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 125 Cr. | 66.8 | 98.7/51.4 | 27.2 | 16.1 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 22.3 Cr. | 4.13 | 7.73/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 28,929.00 Cr | 869.53 | 70.99 | 95.14 | 0.30% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4.10 | 3.97 | 4.65 | 4.96 | 4.98 | 4.90 | 5.15 | 5.44 | 5.70 | 5.42 | 5.70 | 5.83 | 5.51 |
| Expenses | 3.86 | 4.04 | 4.48 | 4.73 | 4.75 | 4.87 | 4.68 | 5.43 | 5.45 | 5.18 | 5.51 | 5.79 | 5.37 |
| Operating Profit | 0.24 | -0.07 | 0.17 | 0.23 | 0.23 | 0.03 | 0.47 | 0.01 | 0.25 | 0.24 | 0.19 | 0.04 | 0.14 |
| OPM % | 5.85% | -1.76% | 3.66% | 4.64% | 4.62% | 0.61% | 9.13% | 0.18% | 4.39% | 4.43% | 3.33% | 0.69% | 2.54% |
| Other Income | 0.05 | 0.05 | 0.08 | 0.06 | 0.06 | 0.07 | 0.09 | 0.07 | 0.08 | 0.10 | 0.13 | 0.11 | 0.07 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.25 | 0.24 | 0.23 | 0.23 | 0.24 | 0.25 | 0.20 | 0.18 | 0.17 | 0.16 | 0.17 | 0.07 | 0.15 |
| Profit before tax | 0.04 | -0.26 | 0.02 | 0.06 | 0.05 | -0.15 | 0.36 | -0.10 | 0.16 | 0.17 | 0.15 | 0.08 | 0.06 |
| Tax % | 0.00% | 0.00% | 0.00% | 133.33% | 0.00% | 0.00% | 0.00% | -10.00% | 0.00% | 0.00% | 0.00% | 62.50% | 0.00% |
| Net Profit | 0.04 | -0.26 | 0.02 | -0.02 | 0.05 | -0.15 | 0.36 | -0.09 | 0.16 | 0.17 | 0.15 | 0.03 | 0.06 |
| EPS in Rs | 0.10 | -0.63 | 0.05 | -0.05 | 0.12 | -0.37 | 0.88 | -0.22 | 0.39 | 0.41 | 0.37 | 0.07 | 0.15 |
Last Updated: August 19, 2025, 8:10 pm
Below is a detailed analysis of the quarterly data for Dhanvantri Jeevan Rekha Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 5.51 Cr.. The value appears to be declining and may need further review. It has decreased from 5.83 Cr. (Mar 2025) to 5.51 Cr., marking a decrease of 0.32 Cr..
- For Expenses, as of Jun 2025, the value is 5.37 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 5.79 Cr. (Mar 2025) to 5.37 Cr., marking a decrease of 0.42 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.14 Cr.. The value appears strong and on an upward trend. It has increased from 0.04 Cr. (Mar 2025) to 0.14 Cr., marking an increase of 0.10 Cr..
- For OPM %, as of Jun 2025, the value is 2.54%. The value appears strong and on an upward trend. It has increased from 0.69% (Mar 2025) to 2.54%, marking an increase of 1.85%.
- For Other Income, as of Jun 2025, the value is 0.07 Cr.. The value appears to be declining and may need further review. It has decreased from 0.11 Cr. (Mar 2025) to 0.07 Cr., marking a decrease of 0.04 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.15 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.07 Cr. (Mar 2025) to 0.15 Cr., marking an increase of 0.08 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.06 Cr.. The value appears to be declining and may need further review. It has decreased from 0.08 Cr. (Mar 2025) to 0.06 Cr., marking a decrease of 0.02 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be improving (decreasing) as expected. It has decreased from 62.50% (Mar 2025) to 0.00%, marking a decrease of 62.50%.
- For Net Profit, as of Jun 2025, the value is 0.06 Cr.. The value appears strong and on an upward trend. It has increased from 0.03 Cr. (Mar 2025) to 0.06 Cr., marking an increase of 0.03 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.15. The value appears strong and on an upward trend. It has increased from 0.07 (Mar 2025) to 0.15, marking an increase of 0.08.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:31 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 7.26 | 7.97 | 9.26 | 11.16 | 13.74 | 16.84 | 18.21 | 9.78 | 16.77 | 17.68 | 20.46 | 22.65 | 22.46 |
| Expenses | 5.93 | 6.44 | 7.81 | 9.53 | 11.89 | 15.61 | 17.55 | 10.53 | 15.27 | 17.10 | 19.62 | 21.93 | 21.85 |
| Operating Profit | 1.33 | 1.53 | 1.45 | 1.63 | 1.85 | 1.23 | 0.66 | -0.75 | 1.50 | 0.58 | 0.84 | 0.72 | 0.61 |
| OPM % | 18.32% | 19.20% | 15.66% | 14.61% | 13.46% | 7.30% | 3.62% | -7.67% | 8.94% | 3.28% | 4.11% | 3.18% | 2.72% |
| Other Income | 0.21 | 0.44 | 0.31 | -0.11 | 0.14 | 0.12 | 0.16 | 0.18 | 0.21 | 0.24 | 0.29 | 0.41 | 0.41 |
| Interest | 0.01 | 0.08 | 0.08 | 0.18 | 0.22 | 0.11 | 0.04 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
| Depreciation | 0.67 | 0.36 | 0.27 | 0.37 | 1.10 | 1.13 | 1.10 | 1.04 | 1.02 | 0.96 | 0.87 | 0.56 | 0.55 |
| Profit before tax | 0.86 | 1.53 | 1.41 | 0.97 | 0.67 | 0.11 | -0.32 | -1.63 | 0.67 | -0.15 | 0.25 | 0.56 | 0.46 |
| Tax % | 39.53% | 29.41% | 32.62% | 43.30% | -7.46% | 63.64% | -15.62% | -12.88% | 28.36% | 46.67% | 36.00% | 8.93% | |
| Net Profit | 0.52 | 1.07 | 0.95 | 0.55 | 0.73 | 0.05 | -0.26 | -1.42 | 0.49 | -0.22 | 0.17 | 0.51 | 0.41 |
| EPS in Rs | 1.27 | 2.61 | 2.32 | 1.34 | 1.78 | 0.12 | -0.63 | -3.46 | 1.20 | -0.54 | 0.41 | 1.24 | 1.00 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 105.77% | -11.21% | -42.11% | 32.73% | -93.15% | -620.00% | -446.15% | 134.51% | -144.90% | 177.27% | 200.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -116.98% | -30.89% | 74.83% | -125.88% | -526.85% | 173.85% | 580.66% | -279.41% | 322.17% | 22.73% |
Dhanvantri Jeevan Rekha Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 4% |
| 3 Years: | 11% |
| TTM: | 6% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -6% |
| 5 Years: | 32% |
| 3 Years: | 1% |
| TTM: | 46% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 26% |
| 3 Years: | 16% |
| 1 Year: | -9% |
| Return on Equity | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | -1% |
| 3 Years: | 2% |
| Last Year: | 5% |
Last Updated: September 5, 2025, 3:11 pm
Balance Sheet
Last Updated: July 25, 2025, 1:26 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 |
| Reserves | 2.50 | 4.29 | 5.25 | 5.79 | 6.52 | 6.57 | 6.30 | 4.88 | 5.37 | 5.15 | 5.32 | 5.98 |
| Borrowings | 0.09 | 0.00 | 0.00 | 1.94 | 1.95 | 0.10 | 0.10 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 1.70 | 2.52 | 3.29 | 4.53 | 3.79 | 4.53 | 4.30 | 4.76 | 4.84 | 4.56 | 5.55 | 4.65 |
| Total Liabilities | 8.44 | 10.96 | 12.69 | 16.41 | 16.41 | 15.35 | 14.85 | 13.86 | 14.36 | 13.86 | 15.02 | 14.78 |
| Fixed Assets | 4.57 | 5.05 | 7.80 | 12.07 | 12.28 | 11.44 | 10.68 | 9.72 | 8.85 | 8.54 | 8.14 | 8.41 |
| CWIP | 0.00 | 1.44 | 0.00 | 0.00 | 0.00 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 3.87 | 4.47 | 4.89 | 4.34 | 4.13 | 3.79 | 4.17 | 4.14 | 5.51 | 5.32 | 6.88 | 6.37 |
| Total Assets | 8.44 | 10.96 | 12.69 | 16.41 | 16.41 | 15.35 | 14.85 | 13.86 | 14.36 | 13.86 | 15.02 | 14.78 |
Below is a detailed analysis of the balance sheet data for Dhanvantri Jeevan Rekha Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 4.15 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 4.15 Cr..
- For Reserves, as of Mar 2025, the value is 5.98 Cr.. The value appears strong and on an upward trend. It has increased from 5.32 Cr. (Mar 2024) to 5.98 Cr., marking an increase of 0.66 Cr..
- For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 4.65 Cr.. The value appears to be improving (decreasing). It has decreased from 5.55 Cr. (Mar 2024) to 4.65 Cr., marking a decrease of 0.90 Cr..
- For Total Liabilities, as of Mar 2025, the value is 14.78 Cr.. The value appears to be improving (decreasing). It has decreased from 15.02 Cr. (Mar 2024) to 14.78 Cr., marking a decrease of 0.24 Cr..
- For Fixed Assets, as of Mar 2025, the value is 8.41 Cr.. The value appears strong and on an upward trend. It has increased from 8.14 Cr. (Mar 2024) to 8.41 Cr., marking an increase of 0.27 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 6.37 Cr.. The value appears to be declining and may need further review. It has decreased from 6.88 Cr. (Mar 2024) to 6.37 Cr., marking a decrease of 0.51 Cr..
- For Total Assets, as of Mar 2025, the value is 14.78 Cr.. The value appears to be declining and may need further review. It has decreased from 15.02 Cr. (Mar 2024) to 14.78 Cr., marking a decrease of 0.24 Cr..
Notably, the Reserves (5.98 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 1.24 | 1.53 | 1.45 | -0.31 | -0.10 | 1.13 | 0.56 | -0.82 | 1.50 | 0.58 | 0.84 | 0.72 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 16.09 | 15.11 | 20.50 | 11.45 | 17.80 | 22.32 | 9.02 | 39.93 | 37.22 | 50.58 | 31.22 | 29.01 |
| Inventory Days | 11.70 | 17.77 | 11.99 | |||||||||
| Days Payable | 0.00 | 0.00 | 0.00 | |||||||||
| Cash Conversion Cycle | 16.09 | 15.11 | 20.50 | 11.45 | 29.50 | 40.09 | 21.00 | 39.93 | 37.22 | 50.58 | 31.22 | 29.01 |
| Working Capital Days | 68.37 | 66.86 | 56.76 | -35.32 | -26.83 | -17.34 | -32.27 | -53.37 | -25.47 | -3.10 | -32.29 | -16.60 |
| ROCE % | 14.04% | 19.76% | 16.70% | 14.94% | 7.27% | 1.88% | -2.62% | -16.39% | 7.41% | -1.49% | 2.77% | 5.82% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.60 | 0.40 | -0.53 | 0.01 | -3.47 |
| Diluted EPS (Rs.) | 1.60 | 0.40 | -0.53 | 0.01 | -3.47 |
| Cash EPS (Rs.) | 2.58 | 2.48 | 1.78 | 3.63 | -0.91 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 24.41 | 22.81 | 22.41 | 22.93 | 21.75 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 24.41 | 22.81 | 22.41 | 22.93 | 21.75 |
| Revenue From Operations / Share (Rs.) | 54.58 | 49.26 | 42.58 | 40.38 | 23.55 |
| PBDIT / Share (Rs.) | 2.72 | 2.71 | 1.97 | 4.11 | -1.36 |
| PBIT / Share (Rs.) | 1.37 | 0.62 | -0.33 | 1.66 | -3.87 |
| PBT / Share (Rs.) | 1.35 | 0.61 | -0.34 | 1.62 | -3.92 |
| Net Profit / Share (Rs.) | 1.23 | 0.39 | -0.52 | 1.18 | -3.43 |
| PBDIT Margin (%) | 4.98 | 5.51 | 4.62 | 10.17 | -5.76 |
| PBIT Margin (%) | 2.51 | 1.27 | -0.77 | 4.11 | -16.44 |
| PBT Margin (%) | 2.47 | 1.24 | -0.81 | 4.01 | -16.66 |
| Net Profit Margin (%) | 2.25 | 0.80 | -1.22 | 2.92 | -14.55 |
| Return on Networth / Equity (%) | 5.03 | 1.74 | -2.32 | 5.14 | -15.75 |
| Return on Capital Employeed (%) | 4.90 | 2.33 | -1.25 | 5.69 | -16.04 |
| Return On Assets (%) | 3.45 | 1.10 | -1.56 | 3.41 | -11.11 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Asset Turnover Ratio (%) | 1.52 | 1.42 | 1.25 | 1.23 | 0.71 |
| Current Ratio (X) | 1.46 | 1.30 | 1.24 | 1.66 | 0.74 |
| Quick Ratio (X) | 1.41 | 1.27 | 1.19 | 1.61 | 0.71 |
| Inventory Turnover Ratio (X) | 39.31 | 0.00 | 0.00 | 0.00 | 23.45 |
| Interest Coverage Ratio (X) | 113.00 | 224.14 | 117.93 | 104.40 | -26.69 |
| Interest Coverage Ratio (Post Tax) (X) | 52.00 | 33.85 | -30.24 | 30.99 | -66.31 |
| Enterprise Value (Cr.) | 6.02 | 7.20 | 4.55 | 5.13 | 2.26 |
| EV / Net Operating Revenue (X) | 0.26 | 0.35 | 0.25 | 0.30 | 0.23 |
| EV / EBITDA (X) | 5.33 | 6.38 | 5.56 | 3.01 | -4.01 |
| MarketCap / Net Operating Revenue (X) | 0.37 | 0.49 | 0.30 | 0.41 | 0.31 |
| Price / BV (X) | 0.84 | 1.07 | 0.58 | 0.72 | 0.34 |
| Price / Net Operating Revenue (X) | 0.37 | 0.49 | 0.30 | 0.41 | 0.31 |
| EarningsYield | 0.05 | 0.01 | -0.04 | 0.07 | -0.45 |
After reviewing the key financial ratios for Dhanvantri Jeevan Rekha Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.60. This value is below the healthy minimum of 5. It has increased from 0.40 (Mar 24) to 1.60, marking an increase of 1.20.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.60. This value is below the healthy minimum of 5. It has increased from 0.40 (Mar 24) to 1.60, marking an increase of 1.20.
- For Cash EPS (Rs.), as of Mar 25, the value is 2.58. This value is below the healthy minimum of 3. It has increased from 2.48 (Mar 24) to 2.58, marking an increase of 0.10.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 24.41. It has increased from 22.81 (Mar 24) to 24.41, marking an increase of 1.60.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 24.41. It has increased from 22.81 (Mar 24) to 24.41, marking an increase of 1.60.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 54.58. It has increased from 49.26 (Mar 24) to 54.58, marking an increase of 5.32.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 2.72. This value is within the healthy range. It has increased from 2.71 (Mar 24) to 2.72, marking an increase of 0.01.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.37. This value is within the healthy range. It has increased from 0.62 (Mar 24) to 1.37, marking an increase of 0.75.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.35. This value is within the healthy range. It has increased from 0.61 (Mar 24) to 1.35, marking an increase of 0.74.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.23. This value is below the healthy minimum of 2. It has increased from 0.39 (Mar 24) to 1.23, marking an increase of 0.84.
- For PBDIT Margin (%), as of Mar 25, the value is 4.98. This value is below the healthy minimum of 10. It has decreased from 5.51 (Mar 24) to 4.98, marking a decrease of 0.53.
- For PBIT Margin (%), as of Mar 25, the value is 2.51. This value is below the healthy minimum of 10. It has increased from 1.27 (Mar 24) to 2.51, marking an increase of 1.24.
- For PBT Margin (%), as of Mar 25, the value is 2.47. This value is below the healthy minimum of 10. It has increased from 1.24 (Mar 24) to 2.47, marking an increase of 1.23.
- For Net Profit Margin (%), as of Mar 25, the value is 2.25. This value is below the healthy minimum of 5. It has increased from 0.80 (Mar 24) to 2.25, marking an increase of 1.45.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.03. This value is below the healthy minimum of 15. It has increased from 1.74 (Mar 24) to 5.03, marking an increase of 3.29.
- For Return on Capital Employeed (%), as of Mar 25, the value is 4.90. This value is below the healthy minimum of 10. It has increased from 2.33 (Mar 24) to 4.90, marking an increase of 2.57.
- For Return On Assets (%), as of Mar 25, the value is 3.45. This value is below the healthy minimum of 5. It has increased from 1.10 (Mar 24) to 3.45, marking an increase of 2.35.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.52. It has increased from 1.42 (Mar 24) to 1.52, marking an increase of 0.10.
- For Current Ratio (X), as of Mar 25, the value is 1.46. This value is below the healthy minimum of 1.5. It has increased from 1.30 (Mar 24) to 1.46, marking an increase of 0.16.
- For Quick Ratio (X), as of Mar 25, the value is 1.41. This value is within the healthy range. It has increased from 1.27 (Mar 24) to 1.41, marking an increase of 0.14.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 39.31. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 39.31, marking an increase of 39.31.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 113.00. This value is within the healthy range. It has decreased from 224.14 (Mar 24) to 113.00, marking a decrease of 111.14.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 52.00. This value is within the healthy range. It has increased from 33.85 (Mar 24) to 52.00, marking an increase of 18.15.
- For Enterprise Value (Cr.), as of Mar 25, the value is 6.02. It has decreased from 7.20 (Mar 24) to 6.02, marking a decrease of 1.18.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.26. This value is below the healthy minimum of 1. It has decreased from 0.35 (Mar 24) to 0.26, marking a decrease of 0.09.
- For EV / EBITDA (X), as of Mar 25, the value is 5.33. This value is within the healthy range. It has decreased from 6.38 (Mar 24) to 5.33, marking a decrease of 1.05.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.37. This value is below the healthy minimum of 1. It has decreased from 0.49 (Mar 24) to 0.37, marking a decrease of 0.12.
- For Price / BV (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has decreased from 1.07 (Mar 24) to 0.84, marking a decrease of 0.23.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.37. This value is below the healthy minimum of 1. It has decreased from 0.49 (Mar 24) to 0.37, marking a decrease of 0.12.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.05, marking an increase of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dhanvantri Jeevan Rekha Ltd:
- Net Profit Margin: 2.25%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.9% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.03% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 52
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.41
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 27 (Industry average Stock P/E: 70.99)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.25%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | 1, Saket, Meerut Uttar Pradesh 250003 | dhanvantrihospital@gmail.com http://www.djrl.org.in |
| Management | |
|---|---|
| Name | Position Held |
| Mrs. Shalini Sharma | Managing Director |
| Mr. Premjit Singh Kashyap | Director |
| Mrs. Meenaakshi Elhence | Director |
| Mr. Tulsi Prasad Sharma | Director |
| Dr. Anil Elhence | Director |
| Mrs. Rowena Sharma | Director |
| Mr. Amitabh Krishna Bhatia | Independent Director |
| Mr. Mohd Harris | Independent Director |
| Mr. Ashok Kumar Singh Chaudhary | Independent Director |
| Mr. Ajay Rajpal | Independent Director |
FAQ
What is the intrinsic value of Dhanvantri Jeevan Rekha Ltd?
Dhanvantri Jeevan Rekha Ltd's intrinsic value (as of 03 November 2025) is 28.30 which is 4.81% higher the current market price of 27.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 11.1 Cr. market cap, FY2025-2026 high/low of 35.9/16.5, reserves of ₹5.98 Cr, and liabilities of 14.78 Cr.
What is the Market Cap of Dhanvantri Jeevan Rekha Ltd?
The Market Cap of Dhanvantri Jeevan Rekha Ltd is 11.1 Cr..
What is the current Stock Price of Dhanvantri Jeevan Rekha Ltd as on 03 November 2025?
The current stock price of Dhanvantri Jeevan Rekha Ltd as on 03 November 2025 is 27.0.
What is the High / Low of Dhanvantri Jeevan Rekha Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Dhanvantri Jeevan Rekha Ltd stocks is 35.9/16.5.
What is the Stock P/E of Dhanvantri Jeevan Rekha Ltd?
The Stock P/E of Dhanvantri Jeevan Rekha Ltd is 27.0.
What is the Book Value of Dhanvantri Jeevan Rekha Ltd?
The Book Value of Dhanvantri Jeevan Rekha Ltd is 24.7.
What is the Dividend Yield of Dhanvantri Jeevan Rekha Ltd?
The Dividend Yield of Dhanvantri Jeevan Rekha Ltd is 0.00 %.
What is the ROCE of Dhanvantri Jeevan Rekha Ltd?
The ROCE of Dhanvantri Jeevan Rekha Ltd is 5.82 %.
What is the ROE of Dhanvantri Jeevan Rekha Ltd?
The ROE of Dhanvantri Jeevan Rekha Ltd is 5.20 %.
What is the Face Value of Dhanvantri Jeevan Rekha Ltd?
The Face Value of Dhanvantri Jeevan Rekha Ltd is 10.0.